Alfasigma increases prefilled syringes and vials capacity in its sterile department at Alanno plant
Italian pharma company Alfasigma has increased its capacity for the production of pre-filled syringes in its sterile department of excellence at its Alanno manufacturing plant.
The sterile department is wholly dedicated to the production of pre-filled syringes, cartridges, and ready-to-use vials, and is equipped with a high-performance, versatile filling line with an output of 36,000 pcs/h.
This high-quality manufacturing performance includes the option to use either peristaltic or volumetric pumps, the ability to manage oxygen-sensitive products, and accuracy in the plunger stopper placement and has 100% in-process control (IPC).
Fully integrated sterilization systems (ovens, autoclaves, passboxes) ensure the safety of the aseptic area in the line, according to top-quality standard requirements.
All equipment is connected to a validated computer system in order to guarantee the complete traceability and integrity of the data.
Given its advanced technical characteristics, this line is particularly suitable for supporting production processes requiring outstanding reliability for the manufacturing of high-value products such as biotechnology compounds, biosimilars, and vaccines.
The expansion has increased Alfasigma’s overall annual production capacity to 150 million pre-filled syringes, which is welcome news given the increased demand related to the current COVID-19 pandemic situation.
Alfasigma is a privately owned, Italy-based integrated multinational pharmaceutical company with revenues in excess of €1 billion, five manufacturing plants, R&D facilities, and 3,000 employees globally. Outside of its core Italian market, Alfasigma has 16 subsidiaries in Europe, Asia, North and Central America, and Africa, and is present in more than 90 countries.
The Alanno plant processes rifaximin, a molecule for the treatment of gastrointestinal disorders, which holds the record for US sales of an Italian-owned drug (over €1.5 billion euros, according to IQVIA).
Click here to download an infographic on Alfasigma's two sterile departments at Alanno.
Click here to download an infographic on Alfasigma's products and services.
Related News
-
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance